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Neutrophil gelatinase-associated lipocalin (NGAL) has been demonstrated to be a novel biomarker in acute and chronic kidney
disease. We hypothesized that 24-hour urinary NGAL excretion may be a predictor for renal damage in patients with systemic
lupus erythematosus (SLE). Thirty-four SLE patients with renal involvement (SLE-renal group), 8 SLE patients without renal
involvement (SLE-nonrenal group), 14 patients with non-SLE autoimmune diseases (disease control or DC group), and 12healthy
volunteers (normal control or NC group) were compared for 24-hour urinary excretion of NGAL and diﬀerent cytokines. We
found that the 24-hour urinary NGAL excretion in the SLE-renal group was higher than that in the SLE-non-renal, DC, and NC
groups. However, the excretion of interleukin-10, transforming growth factor-β1, and tumor necrosis factor-α was not diﬀerent
between the SLE-renal and SLE-non-renal groups. Furthermore, NGAL excretion in the SLE-renal group was correlated with
serum creatinine levels and creatinine clearance, but not with the SLE Disease Activity Index score. Multivariate logistic regression
analysisandreceiveroperatingcharacteristiccurveanalysisrevealedthat24-hoururinaryNGALexcretionisapotentialbiomarker
for renal damage in SLE patients, with higher sensitivity and speciﬁcity than anti-dsDNA antibody titers.
1.Introduction
Systemic lupus erythematosus (SLE) is a chronic inﬂam-
matory autoimmune disease aﬀecting many organ systems.
Lupus nephritis (LN) is a common and serious compli-
cation involving a major organ in patients with SLE.
From one-third to one-half of SLE patients have diﬀerent
degrees of renal damage [1] ranging from asymptomatic
hematuria/proteinuria to overt nephritis, rapidly progressive
glomerulonephritis,nephroticsyndrome,orrenalfailure[2].
Recent advances in the diagnosis and treatment of LN
have resulted in markedly improved renal function and
survival in SLE patients with renal survival rates of 83–92%
and 74–84% after 5 and 10 years, respectively [3]. However,
the incidence of LN ﬂareup in diﬀe r e n ts t u d i e si sv a r i a b l e
from 27–66% [4], rendering LN, a major cause of morbidity
and mortality in SLE patients. Since 10–26% patients with
LN progress to end-stage renal disease [5], early detection
andeﬀectivetreatmentofLNis important fortheprevention
of renal failure or mortality in SLE patients.
At present, renal biopsy remains the gold standard in
establishingthediagnosisandprognosisofLNthatcanguide
treatment decisions. However, renal biopsy is not routinely
performed serially and does not reliably represent the global
status of the kidney [1]. In contrast, other noninvasive
procedures for monitoring LN include the measurement2 Journal of Biomedicine and Biotechnology
of serum creatinine levels, 24-hour creatinine clearance
(Ccr), 24-hour urine protein amounts, antidouble stranded
DNA (anti-dsDNA) antibody titers, levels of complements
3 (C3) and C4, and the presence of urine sediments [2, 6].
Nevertheless, the diagnostic value of these measurements for
LN remains controversial.
Urine is an ideal source of potential biomarkers for LN,
becauseofitseasyaccessibilityandthefactthatitcandirectly
reﬂect the status of local inﬂammation/damage in the
kidney. In recent years, many studies have proposed diﬀerent
cytokines/chemokines such as transforming growth factor
(TGF)-β [7–9], interferon (IFN)-γ, interleukin (IL)-2 [10],
monocyte chemoattractant protein-1/chemokine ligand 2
(MCP-1/CCL2) [7, 11], IFN-γ inducible protein-10/CXC
chemokine ligand-10 (IP-10/CXCL10), CXC chemokine
receptor 3 (CXCR3) [8], and tumor necrosis factor (TNF)—
like weak inducer of apoptosis (TWEAK) [12, 13]a s
well as adhesion molecules including vascular cell adhe-
sive molecule-1 (VCAM-1) and P-selectin [14] as useful
biomarkers for LN [6]. However, none of these molecules
have been validated to date in clinical applications.
Neutrophil gelatinase-associated lipocalin (NGAL), a
25-kDa small protein belonging to the lipocalin protein
superfamily, is specialized in binding and transporting small
hydrophobic molecules including iron [15]. NGAL has been
recently demonstrated to be an early biomarker in acute
kidney injury after cardiopulmonary bypass, major cardiac
surgery, elective cardiac catheterization and angiography,
hemolytic uremic syndrome, and kidney transplantation.
NGAL is also a candidate biomarker for chronic kidney
diseases, such as immunoglobulin A (IgA) nephropathy,
membranous and membranoproliferative glomerulonephri-
tis, autosomal dominant polycystic kidney disease, and pedi-
atric LN [16, 17]. Based on these ﬁndings, we hypothesized
that urinary NGAL excretion may be a potential biomarker
for renal damage/inﬂammation in LN.
In the present study, we measured 24-hour urinary
NGAL excretion using a commercially available enzyme-
linked immunosorbent assay (ELISA) kit in SLE patients
with and without renal involvement and compared this to
the excretion of the cytokines IL-10, TGF-β1, and TNF-α.I n
addition, to determine the speciﬁcity of NGAL for LN, we
also measured 24-hour urinary NGAL excretion in non-SLE
patientswithotherautoimmunediseases.Ourresultssuggest
that urinary NGAL excretion is indeed a potential biomarker
for renal damage in patients with SLE.
2.MaterialsandMethods
2.1. Patients and Controls. Forty-two patients fulﬁlling the
1997 revised American College of Rheumatology classiﬁ-
cation criteria for SLE [18] were recruited. These patients
were further divided into SLE-active nephritis (active LN,
n = 24), SLE-renal (active LN, n = 24; and proteinuria
alone, >0.5g/day, n = 10), and SLE-non-renal (n = 8)
groups. The SLE-active nephritis group was deﬁned as the
presence of any of the following abnormal parameters in the
urinalysis: hematuria (>5 red blood cells/high power ﬁeld
(HPF);exclusionofstones,infection,orothercauses),pyuria
(>5 leukocytes/HPF; exclusion of infection), urinary casts
(granular or red blood cell casts); a >30% increase in serum
creatinine levels within 3 months; or biopsy-proven nephri-
tis. The SLE-renal group included all patients from the SLE-
active nephritis group as well as SLE patients with protein-
uria (>0.5g/day) alone, without abnormal urine sediments.
The SLE-nonrenal group consisted of SLE patients without
abnormal urinalysis results or renal function impairment
on the day of the study. The disease control (DC) group
consisted of 14 patients with non-SLE autoimmune diseases.
Twelve healthy volunteers served as the normal control (NC)
group. Subjects with current infection (especially urinary
tract infection) and diabetes mellitus were excluded. This
study was approved by the local IRB and Ethical Committee,
NationalTaiwanUniversityHospital,Taipei,Taiwan.Written
informed consent was obtained from all participants.
2.2. Data Collection. Medical records of all patients were
reviewed. The demographic, laboratory, and clinical data
were collected and are summarized in Table 1.
2.3.AssessmentofDiseaseActivity. DiseaseactivityoftheSLE
patients was assessed by the SLE Disease Activity Index-2000
(SLEDAI-2K) [19] on the day of urine collection.
2.4. Measurement of Urinary NGAL and Diﬀerent Cytokines
by ELISA. The 24-hour urine amount was measured after
thoroughmixing.TenmLofeachurinesamplewasthencen-
trifuged within 2 hours after collection at 3,000rpm for 10
minutestoremovecellulardebris.Thecleanedurinesamples
were stored at −80◦C until measurement. The concentration
of NGAL, IL-10, TGF-β1, and TNF-α was quantiﬁed by
commercial NGAL (Quantikine; R&D Systems, Inc.), IL-10
(DuoSet; R&D Systems, Inc.), TGF-β1 (Quantikine; R&D
Systems, Inc.), and TNF-α (OptEIA Set; BD Biosciences
Pharmingen) ELISA kits, in accordance with the respective
manufacturer’s instructions. The TGF-β1 ELISA kit detected
the active form of TGF-β1 by treating urine samples with
acid to activate TGF-β1 immediately before measurement.
The values of 24-hour urinary excretion of NGAL, IL-10,
TGF-β1,andTNF-αwerecalculatedbymultiplyingtheurine
concentration by the urine amount.
2.5. Statistical Analysis. Statistical analysis was conducted
using Statistical Package for Social Sciences version 13.0
for Window software (SPSS Inc.). Because the data of
continuous variables were mostly not normally distributed,
they were presented in terms of median with interquar-
tile range (IQR), which represents central tendency and
spread. For continuous variables, testing between 2 groups
was performed by the Mann-Whitney U test. Categorical
variables were compared by Pearson’s Chi-Square test or
by Fisher’s exact test when very small proportions were
analyzed. Correlations among continuous variables were
calculated by the Spearman rank correlation coeﬃcient (rs).
Logistic regression analysis was performed to determine
predictorsforrenaldamageinSLEpatients.TodeterminetheJournal of Biomedicine and Biotechnology 3
Table 1: Demographic, laboratory, and clinical characteristics of the diﬀerent patient groups.a, b
Clinical parameter
SLE
DC
SLE-active
nephritis SLE-renal SLE-non-renal
Patients (number) 24 34 8 14
Age (years) 33 (16) (24) 33 (12) (34) 36 (7) (8) 36 (26) (14)
Female: male ratio 18:6 (24) 27:7 (34) 8:0 (8) 14:0 (14)
Laboratory data
Leukocyte (109/I) 7.26 (4.92) (24) 6.47 (5.47) (34) 6.73 (5.80) (8) 9.33 (9.28) (13)
Neutrophil (109/I) 5.27 (4.62) (16) 4.27 (5.52) (23) 4.48 (5.82) (5) 7.45 (6.62) (6)
Lymphocyte (109/I)†,§§ 0.76 (0.71) (16) 0.64 (0.65) (23) 1.45 (1.30) (5) 2.12 (1.65) (6)
Hemoglobin (g/I)††,§§ 95 (24) (24) 99 (24) (34) 115 (33) (8) 117 (18) (13)
Platelet count (109/I) 210 (180) (24) 199 (145) (34) 252 (334) (8) 198 (159) (13)
Serum creatinine (μmoI/I)††,§§ 124 (283) (24) 106 (160) (34) 71 (9) (8) 62 (88) (14)
Serum albumin(g/I)∗∗,††,&,§§ 28 (8) (23) 30 (8) (31) 43 (3) (7) 41 (7) (12)
24-hour Ccr (mL/sec) 0.72 (1.32) (20) 0.89 (1.29) (24) 1.09 (—) (3) 4.91 (0.27) (7)
24-hour urine protein (g/day)∗∗,††,&,§§ 2.82 (7.59) (23) 2.26 (4.64) (33) 0.06 (0.05) (8) 0.04 (0.11) (13)
ESR 1 hour (mm) 44 (32) (16) 49 (30) (22) 31 (46) (5) 30 (46) (10)
C3 (g/I)∗,††,#,§§ 0.56 (0.47) (23) 0.60 (0.54) (31) 0.80 (0.37) (8) 1.24 (0.41) (12)
C4 (g/I) 0.13 (0.16) (18) 0.14 (0.15) (26) 0.13 (0.13) (8) 0.19 (0.10) (13)
Positive anti-dsDNA†,§ 12/24 (50) 15/32 (46.9) 3/8 (37.5) 0/7 (0)
Disease activity
Total SLEDAI∗∗,& 15 (10) (23) 14 (10) (29) 8 (5) (8) —
Extrarenal SLEDAI 4 (4) (23) 4 (7) (29) 8 (5) (8) —
Renal SLEDAI∗∗,& 12 (4) (23) 8 (8) (32) 0 (0) (8) —
Proteinuria >0.5g/day∗∗,& 19/23 (82.6) 29/33 (87.9) 0/8 (0) —
Hematuria∗∗,& 20/24 (83.3) 20/33 (60.6) 0/8 (0) —
Pyuria∗ 10/24 (41.7) 10/33 (30.3) 0/8 (0) —
Urinary casts 9/24 (37.5) 9/33 (27.3) 0/8 (0) —
Clinical features
Active nephritis 24/24 (100) 24/34 (70.6) 0/8 (0) 0/14 (0)
Leukopenia 1/24 (4.2) 5/34 (14.7) 1/8 (12.5) 0/13 (0)
Lymphopenia†,§§ 13/16 (81.3) 19/23 (82.6) 3/5 (60) 1/6 (16.7)
Thrombocytopenia 2/24 (8.3) 3/34 (8.8) 0/8 (0) 0/13 (0)
Low complement†,§ 20/24 (83.3) 27/33 (81.8) 5/8 (62.5) 6/14 (42.9)
Arthritis 1/24 (4.2) 2/34 (5.9) 0/8 (0) —
Rash 5/24 (20.8) 8/34 (23.5) 2/8 (25) —
Serositis 2/24 (8.3) 2/34 (5.9) 0/8 (0) —
CNS involvement 3/24 (12.5) 5/34 (14.7) 2/8 (25) —
Vasculitis 1/24 (4.2) 3/34 (8.8) 2/8 (25) —
Disease duration (years) 3.5 (7.5) (24) 5.0 (9.5) (34) 3.1 (3.8) (8) —
Drug treatment
Steroids††,§§ 24/24 (100) 34/34 (100) 8/8 (100) 9/14 (64.3)
Daily prednisolone or equivalent dosage
(mg/day)c†,§ 18.4 (17) (24) 18 (14) (34) 13 (20) (8) 7 (20) (13)
Hydroxychloroquine 22/24 (91.7) 30/34 (88.2) 8/8 (100) 12/14 (85.7)
Azathioprine 6/24 (25) 11/34 (32.4) 0/8 (0) 3/14 (21.4)
Mycophenolate mofetil 1/24 (4.2) 2/34 (5.9) 0/8 (0) 0/14 (0)4 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Clinical parameter
SLE
DC
SLE-active
nephritis SLE-renal SLE-non-renal
Cyclophosphamide 4/24 (16.7) 4/34 (11.8) 2/8 (25) 1/14 (7.1)
Aspirin or NSAIDs 9/24 (37.5) 14/34 (41.2) 6/8 (75) 7/14 (50)
ACEIs or ARBs∗,††,§ 10/24 (41.7) 12/34 (35.3) 0/8 (0) 0/14 (0)
Pulse therapyd 11/24 (45.8) 12/34 (35.3) 3/8 (37.5) 3/14 (21.4)
aIn continuous variables, data are shown as median (IQR) (number). In categorical variables, data are shown as number (percent).
b∗P<0.05 and ∗∗P<0.01 for SLE-active nephritis group versus SLE non-renal group; †P<0.05 and ††P<0.01 for SLE-active nephritis group versus DC
group; #P<0.01 for SLE-non-renal group versus DC group;∗∗& < 0.01 for SLE-renal group versus SLE-non-renal group; §P<0.05 and §§P<0.01 for SLE-
renal group versus DC group.
cThe mean daily dosage of prednisolone or its equivalent during the preceding 30 days.
dNumbers of patients who were treated by methylprednisolone or cyclophosphamide pulse therapy during the preceding 30 days.
SLE:systemiclupuserythematosus;DC:diseasecontrol;Ccr:creatinineclearance;ESR:erythrocytesedimentationrate;C3:complement3;C4:complement4;
anti-dsDNA: anti-double stranded DNA; SLEDAI: SLE Disease Activity Index; CNS: central nervous system; NSAIDs: nonsteroidal anti-inﬂammatory drugs;
ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II receptor antagonists; IQR: interquartile range.
Table 2: 24-hour urinary excretion of NGAL, IL-10, TGF-β1, and TNF-α in the study groups.a
SLE patients Controls
Active nephritis Renal Non-renal DC NC
Number 24 34 8 14 12
NGAL (mg/day) 50.41 (199.93) 49.05 (114.45) 21.78 (12.42) 13.94 (12.53) 7.65 (7.64)
IL-10 (ng/day) 2.34 (16.81) 3.45 (21.06) 10.03 (18.27) 13.12 (15.99) 5.40 (24.09)
TGF-β1 (ng/day) 41.54 (75.59) 23.82 (69.08) 16.17 (16.13) 15.57 (14.94) 7.83 (6.39)
TNF-α (ng/day) 6.01 (15.23) 5.85 (17.63) 20.49 (24.26) 26.68 (39.04) 0 (13.65)
aData are shown as median (IQR).
NGAL: neutrophil gelatinase-associated lipocalin; IL-10: interleukin-10; TGF-β1: transforming growth factor-β1; TNF-α: tumor necrosis factor-α;S L E :
systemic lupus erythematosus; DC: disease control; NC: normal control; IQR: interquartile range.
sensitivity, speciﬁcity,positive predictive values,andnegative
predictive values of 24-hour urinary NGAL excretion at dif-
ferent cutoﬀ values for the diagnosis of renal involvement in
SLE patients, a conventional receiver operating characteristic
(ROC) curve was generated. An area under the curve (AUC)
of 0.5 was considered no better than expected by chance,
whereas a value of 1.0 signiﬁed a perfect biomarker. Two-
tailed P values of less than 0.05 were considered statistically
signiﬁcant. For graphing purposes, the highly skewed 24-
hour urinary excretion data of NGAL, IL-10, and TGF-β1
were log-transformed, in which case a constant of 1.00 was
added to each value of urinary NGAL, IL-10, and TGF-β1
excretion in order to move the minimum value to 1.00.
3. Results
3.1. Demographic and Clinical Characteristics of the Study
Groups. The present study comprised 42 SLE patients (ratio
o ff e m a l e st om a l e s ,3 5:7 ;m e d i a na g e ,3 4y e a r s ;I Q R ,1 1 )
including 24 SLE patients with active LN, 10 SLE patients
with proteinuria only, and 8 SLE patients without renal
involvement. In addition, the study included 14 patients
without SLE but with other autoimmune diseases (4 had
Sjogren’s syndrome; 3, anti-phospholipid syndrome; 1, vas-
culitis; 1, autoimmune hemolytic anemia; 1, rheumatoid
arthritis with systemic sclerosis overlap; 1, polymyositis; 1,
adult-onsetStill’sdisease;1,pemphigus;1,acuteurticaria)as
the DC group (ratio of females to males, 14:0; median age,
36 years; IQR, 26) and 12 healthy volunteers as the NC group
(ratio of females to males, 10:2; median age, 32 years; IQR,
12).Therewasnosigniﬁcantdiﬀerenceinageorfemale-male
ratio among SLE, DC, and NC groups. The demographic,
laboratory, and clinical characteristics of the diﬀerent patient
groups are summarized in Table 1. These data reveal that
the SLE-renal group had higher SLE Disease Activity Index
(SLEDAI)scores(median,14;IQR,10versusmedian,8;IQR,
5; P = 0.000) than did the SLE-non-renal group.
3.2. 24-Hour Urinary Excretion of NGAL, IL-10, TGF-β1, and
TNF-α. Urinary NGAL excretion in the SLE-active nephritis
and SLE-renal groups was signiﬁcantly higher than that
in the SLE-non-renal, DC, and NC groups (Figure 1(a)
and Table 2). These results suggest that urinary NGAL
may be a potential biomarker for SLE patients with renal
inﬂammation or damage. Unexpectedly, no signiﬁcant dif-
ference in urinary IL-10 excretion was observed among
these groups (Figure 1(b)). Urinary TGF-β1e x c r e t i o nw a s
found to be higher in the 3 SLE subgroups and in the
DC group than in the NC group (Figure 1(c)); however, no
signiﬁcant diﬀerence was found among the 3 SLE subgroups.
Interestingly, urinary TNF-α e x c r e t i o ni nt h eS L E - a c t i v e
nephritis group was not diﬀerent from that of the NC group.Journal of Biomedicine and Biotechnology 5
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Figure 1: Comparison of 24-hour urinary excretion of neutrophil gelatinase-associated lipocalin (NGAL) (a), interleukin (IL)-10 (b),
transforming growth factor (TGF)-β1 (c), and tumor necrosis factor (TNF)-α (d) in 5 groups: systemic lupus erythematosus (SLE)-active
nephritis (n = 24), SLE-renal (24 SLE-active nephritis + 10 SLE-proteinuria only, n = 34), SLE-non-renal (n = 8), disease control (DC,
n = 14), and normal control (NC, n = 12) groups. †P<0.05 and ††P<0.01, are shown above panels, for comparison among the diﬀerent
patient groups. ∗P<0.05, ∗∗P<0.01, and NS, not signiﬁcant, are shown below the x-axis of panels, in comparison with the NC group. The
median value in each study group is shown by a horizontal line.
However, urinary TNF-α excretion was higher in the SLE-
renal, SLE-non-renal, and DC groups than in the NC group
(Figure 1(d)). On the other hand, there was no signiﬁcant
diﬀerence in urinary TNF-α excretion among the 3 SLE
subgroups. These results may suggest that urinary excretion
of TGF-β1a n dT N F - α, but not IL-10, was higher in patients
with SLE and other autoimmune diseases, whereas urinary
NGAL excretion was higher only in SLE patients with renal
involvement.
3.3. Correlations among 24-Hour Urinary Excretion of
NGAL, IL-10, TGF-β1, and TNF-α in the SLE-Renal Group.
Although urinary NGAL excretion was higher in the SLE-
renal group, it was not correlated with the excretion of IL-10
(Figure 2(a)), TGF-β1( Figure 2(c)), or TNF-α (Figure 2(e)).
These results indicate that NGAL is probably a biomarker
for renal damage, rather than for immune-mediated kidney
inﬂammation as reported by other authors [16, 17]. On
the other hand, a negative correlation was found between
IL-10 and TGF-β1( rs = −0.506, P = 0.001; Figure 2(b)),
whereas a tendency towards positive correlation between IL-
10 and TNF-α (rs = 0.297, P = 0.056; Figure 2(d))a n da
tendency towards negative correlation between TGF-β1a n d
TNF-α (rs = −0.273, P = 0.080; Figure 2(f)) were observed.
These results indicate the presence of an intricate regulatory
network that includes the processes of inﬂammation/anti-
inﬂammation, tissue repair/tissue ﬁbrosis, and cell prolifer-
ation/diﬀerentiation in renal damage sites in SLE patients.
3.4. Correlations of 24-Hour Urinary Excretion of NGAL
with Renal Functional Parameters and Disease Activity in the
SLE-Renal Group. In SLE patients with renal involvement,
urinary NGAL excretion was positively correlated with
serum creatinine levels (rs = 0.394, P = 0.010; Figure 3(a)),
negatively correlated with 24-hour Ccr (rs = −0.435, P =
0.023; Figure 3(b)) and not correlated with serum albumin6 Journal of Biomedicine and Biotechnology
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Figure 2: Correlations among 24-hour urinary excretion of neutrophil gelatinase-associated lipocalin (NGAL), interleukin (IL)-10,
transforming growth factor (TGF)-β1, tumor necrosis factor (TNF)-α in the systemic lupus erythematosus (SLE)-renal group. (a)
Correlation between NGAL and IL-10. (b) Correlation between IL-10 and TGF-β1. (c) Correlation between NGAL and TGF-β1. (d)
Correlation between IL-10 and TNF-α (e) Correlation between NGAL and TNF-α and (f) Correlation between TGF-β1a n dT N F - α.
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Figure 3: Correlations of 24-hour urinary excretion of neutrophil gelatinase-associated lipocalin (NGAL) with renal functional parameters
and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores in the systemic lupus erythematosus (SLE)-renal group. (a)
Correlation between NGAL and serum creatinine levels. (b) Correlation between NGAL and 24-hour creatinine clearance (Ccr). (c)
Correlation between NGAL and SLEDAI scores. ∗P<0.05.
levels (rs = −0.263, P = 0.110), 24-hour urine protein
amounts (rs = 0.288, P = 0.068), C3 levels (rs = 0.015, P =
0.930), C4 levels (rs = 0.292, P = 0.093), and anti-dsDNA
antibody titers (rs = −0.155, P = 0.383) (data not shown).
There was also no signiﬁcant correlation with SLEDAI scores
(rs = 0.034, P = 0.839; Figure 3(c)). These results further
conﬁrm that the higher urinary NGAL excretion in the SLE-
renal group seems to derive from renal damage rather than
from active immune reactions in the kidneys.
3.5. Logistic Regression Analysis of 24-Hour Urinary NGAL
Excretion As a Reliable Predictor for Renal Damage in SLE
Patients. Using a logistic regression univariate model with
renal involvement as the outcome and 24-hour urinary
NGAL excretion as a predictor, we found that urinary NGAL
excretion was a signiﬁcant predictor for the SLE-renal group
in all study patients (P = 0.008; odds ratio (OR), 1.060;
95% conﬁdence interval (CI), 1.015–1.107); however, the
result was not signiﬁcant when the study population was
conﬁned to the SLE patients (P = 0.099; OR, 1.049; 95%
CI, 0.991–1.110). After further adjustment for age and sex,
urinary NGAL excretion remained a signiﬁcant predictor for
the SLE-renal group in all patients (P = 0.013; OR, 1.060;
95% CI, 1.012–1.111).
3.6. ROC Curve Analysis of 24-Hour Urinary NGAL Excretion
to Identify SLE Patients with Renal Involvement. To quantify
the diagnostic value of 24-hour urinary NGAL excretion
in patients with renal involvement, we performed the ROC
curve analysis. When the study population was conﬁned
to the SLE patients, the AUC for urinary NGAL excretion
was 0.755 (P = 0.033; 95% CI, 0.587–0.924; Figure 4(a)).8 Journal of Biomedicine and Biotechnology
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Figure 4: Detection of sensitivity and speciﬁcity of 24-hour urinary neutrophil gelatinase-associated lipocalin (NGAL) excretion (a) and
antidouble stranded DNA (anti-dsDNA) titers (b) for the diagnosis of renal involvement in systemic lupus erythematosus (SLE) patients by
receiver operating characteristic curve (ROC) analysis.
In comparison, the AUC for anti-dsDNA antibody titers
was 0.600 (P = 0.416; 95% CI, 0.336–0.864; Figure 4(b)).
Therefore, urinary NGAL excretion is a better biomarker
than anti-dsDNA antibody titers for SLE patients with
renal involvement in our study. Table 3 lists the calculated
sensitivity, speciﬁcity,positive predictive values,andnegative
predictive values of 24-hour urinary NGAL excretion at
diﬀerent cut-oﬀvalues for the diagnosis of renal involvement
in SLE patients.
4. Discussion
Our study demonstrates that urinary NGAL, rather than
IL-10, TGF-β1, and TNF-α, is a potential biomarker for
renal damage in SLE patients. The evidence is supported
by the following 3 facts: (1) Urinary NGAL excretion was
higher in SLE patients with renal involvement than in the
SLE-non-renal or non-SLE autoimmune disease groups.
(2) Urinary NGAL excretion was positively correlated with
serum creatinine levels and negatively correlated with 24-
hour Ccr in SLE patients with renalinvolvement. (3) Urinary
NGAL excretion had higher sensitivity and speciﬁcity as well
as a higher positive predictive value for the diagnosis of renal
involvement in SLE patients than did anti-dsDNA antibody
titers.
NGAL was originally identiﬁed as a protein associated
with puriﬁed gelatinase from the supernatant of activated
neutrophils [20]. Subsequent murine and human studies
revealed remarkable expression levels of NGAL mRNA and
protein in the tubular cells of early postischemic kidneys
[21]. Accordingly, NGAL was regarded as a novel biomarker
in various types of acute kidney injury and chronic kidney
diseases. It is now conceivable that NGAL is an acute
phase reactant rapidly released from various cell types
including neutrophils, monocytes/macrophages, epithelial
cells, vascular endothelial cells, and hepatocytes [16, 17].
Although the SLE-non-renal group exhibited relatively
lower disease activity (median SLEDAI score, 8) than the
SLE-renal group (median SLEDAI score, 14), we observed
no correlation between urinary NGAL excretion and the
SLEDAI score. Furthermore, no correlation was observed
with IL-10, TGF-β1, or TNF-α levels, which are regarded as
markers of the active immune response in SLE. We postulate
that urinary NGAL excretion is more closely related to renal
damage than to systemic or intrarenal immune reactions.
Our data is compatible with those of other authors who
observed that higher urinary NGAL levels in LN were not
necessarily correlated with SLEDAI scores in both pediatric
[22] and adult SLE patients [23]. In contrast, urinary NGAL
was correlated with worsening renal disease activity in
pediatric SLE patients [22]. Rubinstein et al. [24] argued that
NGALwasasigniﬁcantpredictorofrenaldiseaseactivityand
renal ﬂares in SLE patients.
It is interesting to identify the source of NGAL in the
urine of SLE patients with renal involvement. We believe
that plasma NGAL is unrelated to urinary NGAL in SLE
patients based on the observation that plasma NGAL did
not diﬀer signiﬁcantly between SLE patients with or without
active global or renal disease [22, 23]. Although we did
not measure plasma NGAL in our patients, we deduce that
either enhanced local production from renal tubular cells
or increased NGAL leakage from glomerular capillaries is
the major source of increased urinary NGAL in the SLE-
renal group in this study. Bolignano et al. [16] proposed that
the increase in urinary NGAL in chronic renal proteinuric
diseases is due to massive protein loss that may saturate
megalin-cubilin transporters on renal tubular cells leading toJournal of Biomedicine and Biotechnology 9
Table 3: Sensitivity, speciﬁcity, positive predictive values, and negative predictive values of 24-hour urinary NGAL excretion at diﬀerent
cut-oﬀ values for the diagnosis of renal involvement in SLE patients.
Cutoﬀ value (mg/day) Sensitivity (%) Speciﬁcity (%) Positive predictive value (%) Negative predictive value (%)
24.00 70.8 62.5 85 41.7
27.00 70.8 75 84.5 46.2
31.00 70.8 87.5 94.4 50
36.00 66.7 87.5 94.1 46.7
NGAL: neutrophil gelatinase-associated lipocalin; SLE: systemic lupus erythematosus.
reduced NGAL reabsorption. Consequently, the intratubular
complement cascade activation by persistent proteinuria
would further damage tubular cells that exhibit impaired
reabsorption via megalin-cubilin transporters. In addition to
passiveNGALleakageintotheurine,theinjuredtubularcells
may actively produce NGAL as a compensatory mechanism
against complement-induced oxidative stress and apoptosis.
These ﬁndings suggest that renal damage with or without
inﬂammation may enhance NGAL excretion, as shown in
our SLE-renal group.
NGAL is normally expressed at very low levels in human
renal tubular cells [25]; this is also seen in our study. NGAL
mRNA and protein expression is rapidly induced in the
proximal renal tubular cells after toxic or ischemic kidney
injury [21, 26]. In diabetic mice, increased urinary NGAL
was mainly due to impaired renal reabsorption. In mice
with obstructive nephropathy, NGAL protein was rapidly
synthesized in the distal nephrons in the obstructed side
of the kidneys and in the proximal renal tubules in the
contralateral side [27]. The LCN2 gene, which encoded the
NGAL protein, was markedly expressed in the glomerular
mesangial cells in the presence of nephritogenic murine
anti-dsDNA monoclonal antibodies in vitro and in vivo
[28]. Upregulated glomerular expression of the LCN2 gene
and increased urinary NGAL excretion were also found
in crescentic glomerulonephritis in murine chronic graft-
versus-host-disease (a model for human SLE) [29]. In a
human study on IgA nephropathy, strong staining for the
NGAL protein was found only in the proximal tubules and
not in the glomeruli or tubulointerstitial space in patients
with Lee grade III disease [25].
Cell types other than renal tubular cells in the body,
such as various types of epithelial cells, endothelial cells, or
immune cells, might contribute to urinary NGAL levels in
patientsevenwithoutnephritis.Itisnotsurprisingthatthose
patients without renal involvement, both in the SLE-non-
renal and non-SLE autoimmune disease groups, exhibited
higher urinary NGAL excretion than did normal controls.
The role of NGAL in the pathogenesis of renal damage
remains to be elucidated. In a murine model of ischemic
kidney injury, administration of recombinant NGAL before
ischemia or within 1 hour after reperfusion signiﬁcantly
decreased serum creatinine levels and apoptotic cell num-
bers, but increased the numbers of proliferating tubules cells
[30]. In addition, NGAL also exerted an antiapoptotic eﬀect,
preserved N-cadherin expression in proximal renal tubules,
and upregulated the antioxidative enzyme heme oxygenase-
1 in ischemic murine kidneys [31]. Putting these together,
NGAL may play a protective role in the repair and regen-
eration of injured renal tubular cells. In the present study,
we also investigated the eﬀects of medications including
nephrotoxic agents (such as cyclophosphamide, aspirin, or
nonsteroidal anti-inﬂammatory drugs) or nephroprotective
agents (such as angiotensin-converting enzyme inhibitors
or angiotensin II receptor antagonists) on urinary NGAL
excretion, with inconclusive results.
Drawbacks of the present study include the following.
(1) The patient numbers were relatively small. (2) Rather
than early morning spot urine, we collected 24-hour urine,
which was hard to maintain in a sterile condition; this
might aﬀect the accuracy of NGAL determination. (3)
All SLE and non-SLE patients expressed diverse clinical
manifestations, and disease activity of SLE patients was
uniformly assessed by SLEDAI; this might complicate the
statistical analysis. (4) We used stringent selection criteria
for active nephritis, including the presence of cellular urine
sediments, a >30% increase in serum creatinine levels within
3 months, or biopsy-proven nephritis, which reﬂected active
renal inﬂammation. In consideration of possible irreversible
damage to the glomerular basement membrane and lack
of active renal inﬂammation, we classiﬁed a group of SLE
patients with only proteinuria (>0.5g/day) as the SLE-renal
group along with those that were included in the SLE-active
nephritis group. However, the diagnosis of active nephritis
in our study was primarily based on laboratory data and
rarely on renal pathological ﬁndings. Therefore, we could
not analyze the relationship of urinary NGAL excretion with
histopathologicalchangesinactivenephritis.(5)Weusedthe
commonly used SLEDAI scoring system to assess the disease
activityoftheSLEpatients.Ithastheadvantageoffacilitating
global evaluation of the patients, but lacks a severity grading
that reduces its sensitivity [32, 33]. (6) It was diﬃcult to
analyze the eﬀects of diverse medications on the excretion of
urinary inﬂammatory markers.
5. Conclusion
Our study demonstrated that urinary NGAL is a potential
biomarker for renal damage in SLE patients. Direct demon-
stration of NGAL mRNA and protein expression in the lupus
kidney by in situ hybridization, and immunohistochemical10 Journal of Biomedicine and Biotechnology
staining studies, are needed to clarify the origin of NGAL in
SLE patients.
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